At Aurigene Pharmaceutical Services, we design strategic approaches to improve druggability by improving bioavailability and ADME parameters. We provide end-to-end solutions from discovery to manufacturing.
Our portfolio of peptides ranges from simple side-chain modification upto 80 amino acids to backbone and side-chain modified peptides and derivatized peptides.
Why Aurigene Pharmaceutical Services?
Expertise in peptide optimization to improve pharmacological properties
Core competencies ranging from simple linear peptides to complex forms
One-stop solution from Discovery, Development to Manufacturing of Peptides.
Synthesis, scale-up and peptide discovery capabilities
Advanced analytical tools for peptide characterization
Working with major pharmaceutical companies from USA and Europe.
Large manufacturing capabilities in US FDA inspected sites
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Peptide Synthesis
Resources
JANUARY 04, 2021
Role of Peptide Synthesis Based Drugs
Amino acids, peptides and proteins play multiple roles in the normal functioning of the body.Group of amino acids between 2 to 50 are called peptides. They often act as hormones and play diverse roles in the normal biological processes in the human body such as metabolism, intercellular signaling and neurotransmission.Peptide synthesis based drug have a high pote...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Systematic formulation design - shorten development cost & time
Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
Frequently asked questions
What are the methods for peptide synthesis?
There are three major synthesis routes for peptides, solid phase peptide synthesis (SPPS), solution/liquid phase peptide synthesis (LPPS) and hybrid phase peptide synthesis. Hybrid phase peptide synthesis is a combination of solid and liquid peptide synthesis methods.
What is the use of microwave in peptide synthesis?
Microwave assisted peptide synthesis is one of the most efficient and environmentally friendly method, it enables high throughput synthesis of difficult to make peptides and reduces cycle times to 4 minutes while minimizing the required amount of solvent by 90%.
How long does peptide synthesis take?
Peptide synthesis depends on the required sequence length, complexity, purity and quantity of the peptide, it usually ranges from few days for a peptide to few weeks depending on these variables.
What methods are used by Aurigene to manufacture peptides?
Aurigene has expertise in development and manufacturing of peptides via solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) procedures.
The strategies involved are
- Convergent solid phase peptide synthesis where to fragments can be made separately and couple to make the final peptide
- Hybrid phase peptide synthesis which involves the combination of SPPS & LPPS methods. Our laboratories are equipped with manual and automated (CS Bio) peptide synthesizers to support the peptide synthesis as per the requirement.
What is the typical maximum length of a synthesized peptide?
Depending on the requirements, short and longer peptides can be synthesized between 5mer-50mer. SPPS approach is preferable to generate longer peptides Ex: 50 mer (with 50 amino acids).
Which is the best method for synthesizing of a long chain peptide?
Long chain peptides can be preferably synthesized following Solid Phase Peptide Synthesis (SPPS) procedures. Depending on the length and complexity of the peptide convergent or hybrid approaches can be adopted.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market